24-11-2025 23:02 via medpagetoday.com

Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug

(MedPage Today) -- The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday.
The company shared topline results from the 2-year...
Read more »

Medical news



More Benefits With Coffee, This Time in People With Severe Mental Disorders
Untreated Chronic Thyroid Dysfunction in Moms Tied to Autism in Kids
A White House Plan to Extend Obamacare Subsidies Runs Into Familiar GOP Divisions
Some Older Adults Could Use an RSV Booster Shot, Study Suggests
Mom Charged in Ketoacidosis Death; 15-Day CGM Launches Soon; Long-Acting GLP-1 Win
Can Calorie Restriction Slow Brain Aging? 5 Human Brain Epochs; Anti-Tau Drug Fails
After 5 Years, Acid-Reducer Is Back on the Market
FDA Gives Broad Approval to Gene Therapy for Rare Neurologic Disease
Popular Heart Burn Drugs Linked to Worse Survival in Another Cancer Type
Using Minimal Residual Disease for DLBCL Response Assessment
Where Metabolic Surgery Fits Into the MASH Treatment Landscape
Nurses, Healthcare Groups Up in Arms Over Trump's Student Loan Plan
Why Haven't I Made Friends in Residency?
What a Doctor Can See Is Only Part of the Story
Desktop versie